By Mei-Chun Yang, CEO, GlycoNex
In the competitive landscape of biotechnology, particularly within the rapidly advancing antibody-drug conjugate (ADC) sector, the pressure to innovate and bring products to market efficiently has never been greater.
As the demand for more targeted and effective therapies grows, companies must navigate complex regulatory environments, manage intricate supply chains, and meet stringent quality standards. In-house manufacturing,…
Read More…
Source: https://www.bioprocessonline.com/doc/strategic-advantages-of-manufacturing-adcs-in-house-0001